Integrative omics analyses broaden treatment targets in human cancer

Abstract

BackgroundAlthough large-scale, next-generation sequencing (NGS) studies of cancers hold promise for enabling precision oncology, challenges remain in integrating NGS with clinically validated biomarkers.MethodsTo overcome such challenges, we utilized the Database of Evidence for Precision Oncology (DEPO) to link druggability to genomic, transcriptomic, and proteomic biomarkers. Using a pan-cancer cohort of 6570 tumors, we identified tumors with potentially druggable biomarkers consisting of drug-associated mutations, mRNA expression outliers, and protein/phosphoprotein expression outliers identified by DEPO.ResultsWithin the pan-cancer cohort of 6570 tumors, we found that 3% are druggable based on FDA-approved drug-mutation interactions in specific cancer types. However, mRNA/phosphoprotein/protein expression outliers and drug repurposing across cancer types suggest potential druggability in up to 16% of tumors. The percentage of potential drug-associated tumors can increase to 48% if we consider preclinical evidence. Further, our analyses showed co-occurring potentially druggable multi-omics alterations in 32% of tumors, indicating a role for individualized combinational therapy, with evidence supporting mTOR/PI3K/ESR1 co-inhibition and BRAF/AKT co-inhibition in 1.6 and 0.8% of tumors, respectively. We experimentally validated a subset of putative druggable mutations in BRAF identified by a protein structure-based computational tool. Finally, analysis of a large-scale drug screening dataset lent further evidence supporting repurposing of drugs across cancer types and the use of expression outliers for inferring druggability.ConclusionsOur results suggest that an integrated analysis platform can nominate multi-omics alterations as biomarkers of druggability and aid ongoing efforts to bring precision oncology to patients.Electronic supplementary materialThe online version of this article (10.1186/s13073-018-0564-z) contains supplementary material, which is available to authorized users.

Genomic Characteristics of Triple-Negative Breast Cancer Nominate Molecular Subtypes That Predict Chemotherapy Response

“…Due to the complex interactions between heterogeneous tumor cells and TME, there have been a few successes in attempts to search novel drug targets computationally in TNBC. To reveal the mode of action and to identify novel drug-target relationships, pharmacogenomics approaches utilizing gene expression or mutation profiles have been suggested (15,16). However, most computational methods were performed using genetic profiles of cell lines, and validation was insufficient to follow actual patients' responses.…”

Non-invasive Potential Circulating mRNA Markers for Colorectal Adenoma Using Targeted Sequencing

“…However, mRNA markers can reflect sample information at transcriptome level. For the application of circulating mRNA markers, one of the promising ways is to integrate them with miRNA, ctDNA, methylated cell free DNA and CTCs in order to achieve multi-omics marker panels or screening strategies 26,27 . Tumorigenesis is a complex process involving crosstalk of multiple mechanisms, and many genes are mutually redundant in this process.…”

Targeted Therapy Against the Cell of Origin in Cutaneous Squamous Cell Carcinoma

“…Whilst these results are highly dependent on the background prevalence of genomic features in the dataset in question, they highlight that multi-omics approaches incorporating multiple data types may add value over unilateral approaches. This was shown in human tumour datasets, where integrated approaches leveraging both transcriptomic and genomic data have shown promising results in predicting drug sensitivity [67,68]. Therefore, targeting specific factors that contribute to the tumourigenesis of the cell of origin could add another selectivity level to targeted therapy.…”